HeartMate II Beats Medical Management In Ambulatory Heart Failure Patients
This article was originally published in The Gray Sheet
Executive Summary
The Thoratec-sponsored ROADMAP non-randomized study favored the HeartMate II ventricular assist device over optimal medical management in a set of patients who are less symptomatic than the majority of current VAD patients. But HeartMate II patients experienced more adverse events including strokes and gastrointestinal bleeds.